GLP-1 Comparisons: Wegovy vs. Zepbound, Ozempic vs. Mounjaro & More
The honest head-to-head comparisons most consumer pages won't write because they're afraid to take a position. We test every drug, pull real 2026 pricing, cite the actual clinical trial data, and tell you which fits which patient.
All comparisons
Each comparison is a Dotdash-depth editorial article: side-by-side feature table, real cost comparison, when to choose each, clinical evidence, and 8+ FAQs.
Wegovy vs. Zepbound for 2026: real cost, weight loss percentage, eligibility, savings cards, and side effect profile compared head-to-head by an independent editorial team.
Ozempic vs. Mounjaro for Type 2 diabetes in 2026: A1C reduction, weight loss, savings cards, eligibility, and side effects compared head-to-head.
Ozempic vs. Wegovy for 2026: same semaglutide molecule, different doses, different FDA indications. Cost, coverage, and which to ask for compared.
Mounjaro vs. Zepbound for 2026: same tirzepatide molecule, different FDA indications. Cost, coverage, and which to ask for compared.
Compounded semaglutide and tirzepatide vs. brand-name Ozempic, Wegovy, Mounjaro, and Zepbound in 2026: cost, legality, safety, and which path fits which patient.
GLP-1 comparison FAQ
Which is better for weight loss, Wegovy or Zepbound?
On clinical weight-loss percentage, Zepbound wins (20.9% at 15 mg in SURMOUNT-1 vs. Wegovy's 14.9% at 2.4 mg in STEP-1). On cardiovascular outcome data, Wegovy has the SELECT trial. On cash-pay cost, Zepbound's $399 LillyDirect vials beat NovoCare's $499 Wegovy. Insurance coverage usually picks for you.
Which is better for diabetes, Ozempic or Mounjaro?
Mounjaro outperformed Ozempic head-to-head on A1C reduction and weight loss in the SURPASS-2 trial. Ozempic has stronger cardiovascular outcome data via SUSTAIN-6. For most patients with commercial insurance, both land at $25/month with the savings card.
Are Ozempic and Wegovy the same drug?
Same molecule (semaglutide), same manufacturer (Novo Nordisk), different doses (Ozempic up to 2.0 mg, Wegovy up to 2.4 mg) and different FDA-approved indications (diabetes vs. weight management). The choice between them is determined by your diagnosis and your insurance, not by any pharmacological difference.
Are Mounjaro and Zepbound the same drug?
Identical molecule (tirzepatide), identical doses, same manufacturer (Eli Lilly). The only difference is the FDA-approved label: Mounjaro for Type 2 diabetes, Zepbound for chronic weight management. Lilly built Zepbound as a separate brand to make insurance coverage of weight-loss prescribing cleaner.
Compounded GLP-1 vs. brand-name — which should I choose?
If your commercial insurance covers the brand drug, the manufacturer savings card lands you at $0–$25/month — go brand. If you're cash-pay or federal-plan-enrolled (Medicare, Medicaid, VA), compounded semaglutide or tirzepatide from a state-licensed pharmacy is typically $179–$499/month — significantly cheaper but not FDA-reviewed as a specific preparation.
Can I switch between GLP-1 drugs?
Yes, with clinician guidance. You don't transfer your dose level — you restart the new drug at its starter titration (e.g., Zepbound at 2.5 mg, Wegovy at 0.25 mg) and titrate up. There's no required washout period between them. Common switches: Ozempic → Wegovy when transitioning from off-label diabetes-drug weight loss to the on-label obesity indication; Wegovy → Zepbound for stronger weight-loss response.